1
|
Fioranelli M, Sepehri A, Roccia MG, Jafferany M, Olisova OY, Lomonosov KM, Lotti T. RETRACTED: 5G Technology and induction of coronavirus in skin cells. J BIOL REG HOMEOS AG 2020; 34:4R. [PMID: 32746604 DOI: 10.23812/20-269-e-4r] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This article has been retracted at the request of the Editor. After a thorough investigation the Editor-in-Chief has retracted this article as it showed evidence of substantial manipulation of the peer review.
Collapse
Affiliation(s)
- M Fioranelli
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
| | - A Sepehri
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
| | - M G Roccia
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
| | | | - O Y Olisova
- Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - K M Lomonosov
- Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - T Lotti
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
- Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
2
|
Fioranelli M, Sepehri A, Roccia MG, Jafferany M, Olisova OY, Lomonosov KM, Lotti T. RETRACTED: 5G Technology and induction of coronavirus in skin cells. J BIOL REG HOMEOS AG 2020:10.23812/20-269-E-4. [PMID: 32668870 DOI: 10.23812/20-269-e-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Ahead of Print article withdrawn by publisher.
Collapse
Affiliation(s)
- M Fioranelli
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
| | - A Sepehri
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
| | - M G Roccia
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
| | | | - O Y Olisova
- Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - K M Lomonosov
- Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - T Lotti
- Department of Nuclear, Sub-nuclear and Radiation Physics, G. Marconi University, Rome, Italy
- Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
3
|
Vaccaro M, Lentini M, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C. Hard to face: cutaneous malignant melanoma. J BIOL REG HOMEOS AG 2017; 31:53-55. [PMID: 28702965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
An 88-year-old Caucasian man recently sought medical attention due to recrudescence of skin disease in the area of previously excised nodule (in 2002) on the nose dorsum. The original lesion was clinically considered as a pigmented basal cell carcinoma, after which histological examination revealed a superficial spreading melanoma in vertical growth face (Clark level IV; Breslow thickness 2.1 mm) arising from a pre-existing nevus. The adjacent skin also showed significant actinic damage both in the epidermis and in the dermis. A sentinel node was positive (micrometastases of melanoma) and radical lymph node dissection of the neck was performed. Other lymph nodes did not contain metastasis. Computed tomography scans of brain, chest, abdomen and pelvis performed at that time showed no evidence of systemic disease.
Collapse
Affiliation(s)
- M Vaccaro
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - M Lentini
- Department of Human Pathology, University of Messina, Messina, Italy
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Chair of Dermatology, University of Rome "G. Marconi", Rome, Italy
| | - C Guarneri
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| |
Collapse
|
4
|
Guarneri C, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri F. Possible role of Helicobacter pylori in diseases of dermatological interest. J BIOL REG HOMEOS AG 2017; 31:57-77. [PMID: 28702966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. pylori infection were suggested in diseases of dermatological interest such as chronic urticaria, rosacea, Henoch-Schoenleins purpura, idiopathic thrombocytopenic purpura, cutaneous and oral lichen planus, atopic dermatitis, recurrent aphthous stomatitis, systemic sclerosis, psoriasis, Sjögrens syndrome, Behçet's disease, pruritus, alopecia areata, primary cutaneous marginal zone B-cell lymphomas, vitiligo, chronic prurigo, multiformis, prurigo nodularis, leukocytoclastic vasculitis, prurigo pigmentosa, eczema nummulare, primary cutaneous MALT-type lymphoma, sublamina densa-type linear IgA bullous dermatosis, Sweet's syndrome, cutaneous T-cell pseudolymphoma and pemphigus vulgaris. A critical review of the literature up to May 2017 shows clear evidence of H. pylori involvement only for some of the above purported associations, while in the majority of cases data appear contrasting and/or obtained on a not adequately large study population. Further clinical and laboratory research, with more adequate methodological and statistical basis, is required to assess the actual existence and relevance of many purported associations, as well as the possible role of H. pylori and the underlying pathogenic mechanisms.
Collapse
Affiliation(s)
- C Guarneri
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Chair of Dermatology, University of Rome "G. Marconi", Rome, Italy
| | - F Guarneri
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| |
Collapse
|
5
|
Vaccaro M, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C. Unexpected parasitosis. J BIOL REG HOMEOS AG 2017; 31:35-37. [PMID: 28702962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Neotrombicula autumnalis is an arthropod living in the soil and parasitizes animals only in its larval stage. Depending on climatic conditions, one to five life cycles can take place in a single year. Human infestation is probably underestimated and can be easily missed due to non-pathognomonic cutaneous manifestations in absence of systemic signs. We describe a case of human trombiculiasis and discuss the diagnostic and therapeutic management of this ‘synanthropic’ dermatosis.
Collapse
Affiliation(s)
- M Vaccaro
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - C Guarneri
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| |
Collapse
|
6
|
Rovesti M, Satolli F, Zucchi A, Gandolfi M, Fioranelli M, Roccia MG, Boccalari M, França K, Lotti J, Zerbinati N, Lotti T, Feliciani C. Between history and gossip: the state of women relative to syphilis, a traditionally male disease. J BIOL REG HOMEOS AG 2017; 31:187-191. [PMID: 28702981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Despite the new World Health Organization data remind us how syphilis is a disease which affects both sexes equally, this pathology has always been mainly considered a male disease. While several famous men are known to be affected by syphilis, there are very few women affected by this pathology of which we have historical records. Through the lives of Mary Todd Lincoln, Catherine of Aragon, Karen Blixen and Florence Foster Jenkins, this article would like to grant dignity to all the women who contracted syphilis in the wrong historical era where, for a woman, admitting to contracting it was shameful. Through the important women who lived their lives fighting against this disease and its complications, we would like to pay tribute to all those women who still today, in an era of antibiotics and where syphilis is a treatable pathology, they cannot be cured because they are both geographically and socially disadvantaged.
Collapse
Affiliation(s)
- M Rovesti
- Department of Dermatology, University of Parma, Parma, Italy
| | - F Satolli
- Department of Dermatology, University of Parma, Parma, Italy
| | - A Zucchi
- Department of Dermatology, University of Parma, Parma, Italy
| | - M Gandolfi
- Department of Dermatology, University of Parma, Parma, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | | | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioural Sciences, Institute for Bioethics and Health Policy, University of Miami Miller School of Medicine, Miami, FL, U.S.A
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - N Zerbinati
- Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - C Feliciani
- Department of Dermatology, University of Parma, Parma, Italy
| |
Collapse
|
7
|
Gianfaldoni S, Wollina U, Lotti J, Gianfaldoni R, Lotti T, Fioranelli M, Roccia MG. History of venous leg ulcers. J BIOL REG HOMEOS AG 2017; 31:107-120. [PMID: 28702971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
To retrieve the history of venous ulcers and of skin lesions in general, we must go back to the appearance of human beings on earth. It is interesting to note that cutaneous injuries evolved parallel to human society. An essential first step in the pathogenesis of ulcers was represented by the transition of the quadruped man to Homo Erectus. This condition was characterized by a greater gravitational pressure on the lower limbs, with consequences on the peripheral venous system. Furthermore, human evolution was characterized by an increased risk of traumatic injuries, secondary to his natural need to create fire and hunt (e.g. stones, iron, fire, animal fighting). Humans then began to fight one another until they came to real wars, with increased frequency of wounds and infectious complications. The situation degraded with the introduction of horse riding, introduced by the Scites, who first tamed animals in the 7th century BC. This condition exhibited iliac veins at compression phenomena, favouring the venous stasis. With time, man continued to evolve until the modern age, which is characterized by increased risk factors for venous wounds such as poor physical activity and dietary errors (1, 2).
Collapse
Affiliation(s)
- S Gianfaldoni
- Department of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - R Gianfaldoni
- Department of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| |
Collapse
|
8
|
Rovesti M, Satolli F, Zucchi A, Gandolfi M, Fioranelli M, Roccia MG, Boccalari M, França K, Lotti J, Zerbinati N, Lotti T, Feliciani C. A short novel about the spread of two important diseases in history: syphilis and SARS. J BIOL REG HOMEOS AG 2017; 31:183-186. [PMID: 28702980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Throughout the centuries, the undefended nature of man has very often manifested in cases of epidemics, which have determined scenarios of suffering and death. Through “historical” observation lens, it is possible to understand the relationship between the spread of viruses, bacteria and parasites responsible for these epidemics and the displacement of ancient or contemporary travellers. We have analysed two infective diseases, syphilis and SARS, and their role in history and in medicine.
Collapse
Affiliation(s)
- M Rovesti
- Department of Dermatology, University of Parma, Parma, Italy
| | - F Satolli
- Department of Dermatology, University of Parma, Parma, Italy
| | - A Zucchi
- Department of Dermatology, University of Parma, Parma, Italy
| | - M Gandolfi
- Department of Dermatology, University of Parma, Parma, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | | | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioural Sciences, Institute for Bioethics and Health Policy, University of Miami Miller School of Medicine, Miami, FL, U.S.A
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - N Zerbinati
- Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - C Feliciani
- Department of Dermatology, University of Parma, Parma, Italy
| |
Collapse
|
9
|
Unal E, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C, Parlak N. Duncan’s dermatosis: from the “terra firma-forme” to a possible syndromic condition. The story of a dirty disease. J BIOL REG HOMEOS AG 2017; 31:39-44. [PMID: 28702963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Since its first description by Duncan, Tschen and Knox in 1987 in the former Archives of Dermatology (1), “Terra firma-forme dermatosis” has been variously described in medical literature, representing a strange, probably underestimated, cutaneous disease. During the last 40 years, the condition has been recorded as an undesirable as well as unexplained event, occurring mainly in childhood, characterized by a brownish-black appearance of the whole skin, resembling dirt. Recently, authors described several cases of atypical patterns of the disease, sometimes with impressing topographic clinical pictures, evocative for syndromic phenotypes. Thanks to more careful examination of the tegument, often with the aid of non-invasive diagnostic tools, attention to this disease is growing. This brief review summarizes the state of the art on the topic, through an historical overview of what is known of this ‘dirty’ dermatosis.
Collapse
Affiliation(s)
- E Unal
- Department of Dermatology, Yildirim Beyazit University Yenimahalle Training and Research Hospital, Ankara, Turkey
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - C Guarneri
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - N Parlak
- Department of Dermatology, Yildirim Beyazit University Yenimahalle Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
10
|
Agrawal M, Lotti J, França K, Fioranelli M, Roccia MG, Lotti T. The evolution of artificial hair implantation. J BIOL REG HOMEOS AG 2017; 31:169-177. [PMID: 28702978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
From the beginning, artificial hair implantation has aroused a lot of interest, sometimes controversial, in the field of hair restoration. The artificial fiber must be of high quality and biocompatible. Biofibre® is a very fine fiber having diameter of 80 m. The standard length of this fiber is 15 or 30 cm, to satisfy multiple patient requests. They are available in 13 colors and 3 different shapes (straight, wavy and curly). Artificial hair implant is indicated in all (male and female) cases of androgenetic alopecia, especially for those who show dismal response to medical therapies and have poor donor area supply for hair transplantation. It has also shown good results to treat scars. One hundred thirty-three cases of androgenetic alopecia were treated with Biofibre® and followed-up for 3 years. A clinical evaluation was carried out after 1 month, 4 months and every other 4 months after the implant. The fiber loss was no more than 10% per year in 91.4% of the cases, 15% in 7.8% of the cases and 20% in 0.8% of the cases. 96.2% of patients declared themselves to be satisfied with the result of the implant while 3.8% declared to be not satisfied. To conclude, modern artificial hair implantation can be considered a safe and easy mode of hair restoration, for male and female patients, especially in donor depleted cases or when an immediate aesthetic result is required.
Collapse
Affiliation(s)
- M Agrawal
- Fortis Hospital, Shalimar Bagh, New Delhi, Delhi, India
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami Miller School of Medicine, Miami, FL, U.S.A
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Chair of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| |
Collapse
|
11
|
Cona F, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C. Cutaneous manifestations in Steinert’s disease. Apropos of four clinical cases. J BIOL REG HOMEOS AG 2017; 31:23-33. [PMID: 28702961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Myotonic dystrophy type 1 (MD1) (OMIM 160900, Steinert disease) is the most common muscular disease, with an estimated worldwide prevalence ranging from 0.5 to 18/10,000 (1). MD1 is an autosomal dominant multisystem disorder that affects skeletal and smooth muscles as well as eyes, heart, endocrine system, and central nervous system. Available data on skin and adnexal involvement that has been demonstrated as a hallmark of the neurological disease are still poor. The aim of this case report-based, mini review on MD1 and skin is to highlight the importance of such superficial signs to be easily detected in the physical examination, and to evaluate the occurrence of these cutaneous manifestations in presence of various degrees of the disease and gene mutations.
Collapse
Affiliation(s)
- F Cona
- Umberto I, City Hospital of Enna, Enna, Italy
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome "G. Marconi", Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Chair of Dermatology, University of Rome "G. Marconi", Rome, Italy
| | - C Guarneri
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| |
Collapse
|
12
|
Gianfaldoni S, Lotti J, Roccia MG, Fioranelli M, Gianfaldoni R, Lotti T. Stigmata in the history: between faith, mysticism and science. J BIOL REG HOMEOS AG 2017; 31:45-52. [PMID: 28702964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Stigmata are one of the most ancient and fascinating mysteries of the Christian religion. The word “stigmata” derives by the Greek “stigma”, that means sign, mark. Classically, stigmata are the sores inflicted on Jesus Christ during his passion and crucifixion. Today, the term stigmatized has been extended to designate several cases of individuals, who show skin sores similar to those of Christ. The Authors report a brief history of stigmata, trying to give an explanation to such a fascinating phenomenon.
Collapse
Affiliation(s)
- S Gianfaldoni
- Department of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - J Lotti
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - M Fioranelli
- Department of Nuclear, Subnuclear and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy
| | - R Gianfaldoni
- Department of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome “G. Marconi”, Rome, Italy
| |
Collapse
|
13
|
Wollina U, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. A multi-centred open trial of Dr Michaels® (also branded as Soratinex®) topical product family in psoriasis. J BIOL REG HOMEOS AG 2016; 30:1-7. [PMID: 27498651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic, recurring skin disease affecting 2-4% of the population. Genetic predisposition and precipitating factors play a role in its etiology. The disease can occur in any age or gender group. The most frequently affected areas of the body include scalp, extensor surfaces of the extremities, skin folds and nails. While a number of therapies exist for the treatment of psoriasis with a total resolution of the skin, achieving remission in a high percentage of sufferers, a treatment that results in the maintenance of remission and is free of side effects is still a desirable goal. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Soratinex®) topical product family in psoriasis, in terms of decreasing parakeratosis, inflammation, infiltration and involved area. Seven-hundred-and-twenty-two subjects, mean age 42.3 years (range: 18-68 years) with mild to moderately severe psoriasis, with no other current anti-psoriatic therapy, consisting of 382 males and 340 females, above 18 years of age were included and the observations were subjected to statistical analysis. Triphasic application of Dr Michaels® (Soratinex®) products was employed for 8 weeks, using Cleansing Gel, Scalp and Body Ointment and Skin Conditioner. The treatment proved to be ineffective for 22 patients (3.1%) out of 722. 84 patients (11.6%) had moderate improvement with 26-50% of cleared skin lesions; 102 patients (14.1%) had good improvement with 51-75% of cleared skin lesions; 484 patients (67.0%) experienced outstanding improvement with 76-100% of the cleared skin lesions, with 52% of them achieving total resolution. Twelve patients worsened and discontinued treatment; 18 patients discontinued because of non-compliance; 33 patients developed folliculitis as a side effect. Based on the results of this study, the Dr Michaels® (Soratinex®) product family can be successfully applied in mild to moderately severe psoriasis when considering the exclusion criteria.
Collapse
Affiliation(s)
- U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine - Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa. Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
14
|
Barygina V, Becatti M, Mannucci A, Taddei N, Tirant M, Hercogovấ J, França K, Fioranelli M, Roccia MG, Tchernev G, Wollina U, Lotti T, Fiorillo C. Rapid communication: a vegetable oil extract restores redox status in fibroblasts from psoriatic patients. J BIOL REG HOMEOS AG 2016; 30:129-131. [PMID: 27498670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is an inflammatory skin disease that affects 2-5% of the worldwide population. It is a chronic immune-mediated hyperproliferative inflammatory skin disease of unknown etiology, characterized by the appearance of sore patches of thick, red skin with silvery scales.
Collapse
Affiliation(s)
- V Barygina
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence Italy
| | - M Becatti
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence Italy
| | - A Mannucci
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence Italy
| | - N Taddei
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence Italy
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - K França
- Department of Dermatology and Cutaneous Surgery,
Department of Psychiatry and Behavioral Sciences,
Institute for Bioethics and Health Policy,
University of Miami, Miller School of Medicine, Miami, FL, USA
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| | - C Fiorillo
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence Italy
| |
Collapse
|
15
|
Maximov GK, Maximov KG, Chokoeva AA, Lotti T, Wollina U, Patterson JW, Guarneri C, Tana C, Fioranelli M, Roccia MG, Kanazawa N, Tchernev G. 5-hydroxytryptamine and Lyme disease. Opportunity for a novel therapy to reduce the cerebellar tremor? J BIOL REG HOMEOS AG 2016; 30:7-12. [PMID: 27373127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Lyme boreliosis is caused by the spirochete Borrelia burdorferi, which is transmitted by ticks. A 59 year-old woman developed pyrexia, strong headaches, ataxia, dysarthria and tremor of the limbs after a tick bite. She was unable to work and eat on her own. She was hospitalized three times and diagnosed with cerebellar intention tremor, cerebellar ataxia, dysarthria, bilateral horizontal gaze paralysis and a central lesion of the left facial nerve. There were no pyramidal, sensory or psychiatric disturbances. The brain MRI showed multifocal leucoencephalopathy with many hyperintense areas in both hemispheres, as well as in the left superior pedunculus cerebellaris. Diagnosis was confirmed by serologic examination. Treatment with cephtriaxone, doxycycline, methylprednisolone, cephixime and ciprofloxacine was administered without effect on the tremor, ataxia and horizontal gaze paralysis. Treatment was then administered with 5-hydroxytriptamine (5-HT) in increased doses. The result of the three-month treatment with 5-HT was a gradual diminution of the tremor and the ataxia and an increase in the ability to eat, walk and work independently.
Collapse
Affiliation(s)
- G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K G Maximov
- Neuromed Center for Neurology and Neurosurgery, Military Medical Academy, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - J W Patterson
- University of Virginia Health System, Department of Pathology, Charlottesville, VA USA
| | - C Guarneri
- Department of Clinical and Experimental Medicine, Section of Dermatology, University Hospital of Messina, Messina, Italy
| | - C Tana
- Internal Medicine Unit, Guastalla Hospital, AUSL Reggio Emilia, Reggio Emilia, Italy
| | - M Fioranelli
- History Department, G.Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - N Kanazawa
- Department of Dermatology, Wakayama Medical University, Wakayama, Japan
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| |
Collapse
|
16
|
Tchernev G, Sheta M, Rahoui M, Chokoeva AA, Wollina U, Maximov GK, Patterson JW, Fioranelli M, Roccia MG, Ananiev J, Lotti T. Biofibre hair implant: what is new, what is true? J BIOL REG HOMEOS AG 2016; 30:27-34. [PMID: 27373131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Ensuring the safety of hair implant fibers is essential. At the same time, good aesthetic quality and durability should also be considered in order to maintain expected result over the years. The main features required are biocompatibility, resistance to traction, absence of capillarity, resistance to physical-chemical stress, and low tissue trauma, in addition to good aesthetics. Biofibre® medical hair prosthetic fibers meet all the biocompatibility and safety requirements established by international standards for medical devices. They are available in 13 colors, with different lengths (15, 30 or 45 cm) and various shapes (straight, wavy, curly and afro). Biofibre® hair implants are indicated for diffuse hair loss or hair thinning in cases where an immediate aesthetic result is required, when patients request minor surgery without hospitalization, both for male and female patients, in combination with other hair restoration techniques to improve the final aesthetic result, to correct scars or scalp burns and in cases of poor donor areas. Biofibre® Hair Implant is in fact a minor surgery technique, performed under local anesthesia by either a manual implanter or an automatic machine which enables an immediate aesthetic result and the desired quantity of hair without pain or hospitalization. Clinical and histological studies have demonstrated that Biofibre® hair Implants are safe and well tolerated by patients and can be totally reversible if the need arises. This technique requires good after-care, periodical check-ups and yearly implant re-touches to maintain the best cosmetic result.
Collapse
Affiliation(s)
- G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - M Sheta
- Al Mansour Dermatologic Clinic, Kuwait City, Kuwait
| | - M Rahoui
- Clinique Cheveux et Lifting, Tunis, Tunisia
| | - A A Chokoeva
- Onkoderma-Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - J W Patterson
- University of Virginia Health System, Department of Pathology, Charlottesville, VA USA
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - J Ananiev
- Department of General and Clinical Pathology, Forensic Medicine and Deontology, Trakia University, Armeiska str.11, Stara Zagora, Bulgaria
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
17
|
Tirant M, Bayer P, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of facial systemic lupus erythematosus lesions with Dr Michaels® (Soratinex®) product family. A case report. J BIOL REG HOMEOS AG 2016; 30:95-102. [PMID: 27498665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the bodys immune system mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain and other organs. We report the case of a 7-year-old female patient with facial lesions of SLE since the age of 5. There was no significant family history and patient had been a healthy child from birth. The child presented with a malar rash, also known as a butterfly rash, with distribution over the cheeks but sparing the nasal bridge. This case represents the efficacy of the Dr. Michaels® (Soratinex®) product family in the successful resolution of facial lesions of SLE.
Collapse
Affiliation(s)
- M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department of Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
18
|
França K, Novotny F, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Roccia MG, Lotti T. Efficacy and safety of Dr Michaels® (Soratinex®) product family for the topical treatment of psoriasis: a monitored status study. J BIOL REG HOMEOS AG 2016; 30:115-119. [PMID: 27498668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The aim of the study was to investigate the efficacy and safety of Michaels® (Soratinex®) remedies in patients suffering from chronic plaque psoriasis in a Czech population. Seventy-five (34 female/41 male) patients, aged 18-72 years old (mean age: 38.5 years) with mild to severe plaque psoriasis participated in the study. The products, including cleansing gel, ointment and skin conditioner, containing fruit acid complex, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Histologic variables and various blood picture parameters, including FW, glucose, cholesterol, triacylglyceroles, bilirubin, GMT, ALT, AST, creatinine, uric acid and urea in blood were monitored, before and after therapy with Michaels® (Soratinex®) treatment. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done at time 0, and after 2, 4, 6 and 8 weeks. Patients improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks using Dr Michaels® (Soratinex®) treatment course, 5 patients had a moderate improvement, with the resolution of 25-50% of skin lesions; 11 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 50 patients had an outstanding improvement, with the regression of 76-100% of lesions. Only 4 patients did not achieve an improvement of psoriasis. Six patients experienced folliculitis, which resolved without cessation of treatment. Three patients worsened and discontinued treatment. Six patients dropped out because of non-compliance. The blood results and histologic findings were all normal. Our investigation shows that Dr Michaels® (Soratinex®) products can be safely and successfully used in the treatment of chronic plaque psoriasis.
Collapse
Affiliation(s)
- K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - F Novotny
- PROSANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
19
|
Stowman AM, Griffin MM, Kanner WA, Tchernev G, Chokoeva AA, Wollina U, Lotti T, Fioranelli M, Roccia MG, Maximov GK, Patterson JW. Coexistent trichilemmoma and trichoblastoma without associated nevus sebaceus. J BIOL REG HOMEOS AG 2016; 30:17-20. [PMID: 27373129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Trichilemmoma and trichoblastoma are benign adnexal neoplasms derived from the hair follicle unit. While trichilemmomas are closely associated with the epidermis, trichoblastomas are found within the dermis and subcutaneous tissue. Both tumors have been reported to arise within nevus sebaceus of Jadassohn (NSJ). We present a 42-year-old white male with a 5 mm crusted, erythematous papule on the right occipital scalp that had been present for years. A shave biopsy was performed and read as trichilemmoma involving the biopsy base. The patient returned for follow-up 2 months later with recurrence of a crusted papule, measuring 9 mm in greatest diameter at the site of the previous biopsy. The lesion was excised for complete histologic evaluation, diagnosed as trichilemmoma with verrucoid features and associated basaloid proliferation with adnexal differentiation, again involving the biopsy base. The lesion recurred 2 months later in the form of an 8 mm multilobulated pink nodule. It was again excised and diagnosed as trichoblastoma with overlying trichilemmoma. The significance of this finding is that coexistent lesions do not necessarily necessitate a preexisting nevus sebaceous. Rather, this finding supports the notion of a common stem cell capable of differentiating toward the various portions of the hair follicle unit and adnexal structures. The idea is that any portion of the skin adnexal structure may develop out of a pluripotential germ cell and develop into a tumor.
Collapse
Affiliation(s)
- A M Stowman
- Department of Medical 1Department of Pathology, Division of Dermatopathology, University of Virginia Health System, Charlottesville, Virginia
| | - M M Griffin
- University of South Carolina School of Medicine Greenville, Greenville, South Carolina
| | - W A Kanner
- University of South Carolina School of Medicine Greenville, Greenville, South Carolina; Pathology Consultants, Greenville, South Carolina
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-Interventional Studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - J W Patterson
- Department of Medical 1Department of Pathology, Division of Dermatopathology, University of Virginia Health System, Charlottesville, Virginia
| |
Collapse
|
20
|
Fioranelli M, Hercogovấ J, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Clinical evaluation of the effectiveness of Dr Michaels® (also branded as Soratinex®) products in the topical treatment of patients with plaque psoriasis. J BIOL REG HOMEOS AG 2016; 30:29-34. [PMID: 27498655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is generally considered as an autoimmune inflammatory cutaneous-systemic disease, with chronic course and high rate of recurrence, while its high risk of comorbidities affect the patients quality of life significantly. Despite the good therapeutic response, most of the available options show tendency for poor tolerance and high rate of occurrence of side effects. Therefore, the interest of patients and doctors to investigate the possibility of treating psoriasis with natural substances is not surprising. The aim of this study was to investigate the efficacy and safety of the herbal skin-care product Dr Michaels® (Soratinex®) for the management of chronic plaque psoriasis, within a 6 to 8 week treatment course. Thirty patients of both sexes, aged between 24 and 70 years with mild to moderate psoriasis vulgaris were included in this study. The products of Dr Michaels® (Soratinex®) were applied in sequence: cleansing gel, ointment after 3-4 minutes and tonic care (for the fire-smeared ointment) 2 times per day for restorative care and cleansing gel for psoriasis within scalp 3 times a week. The study lasted six weeks. The severity and extent of the lesions were evaluated by PASI score (Psoriasis Area and Severity Index). Based on the obtained result, the products of Dr Michaels® (Soratinex®) have proved to be effective in the treatment of mild and moderate psoriasis vulgaris. In the study group, no improvement was observed in 10% of patients, a slight improvement in 20%, good in 40% and very good in 16.6% of patients.
Collapse
Affiliation(s)
- M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine - Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa. Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
21
|
França K, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Bayer P, Coburn M, Anderson P, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Novotny F, Roccia MG, Maximov GK, Lotti T. Investigation of the efficacy and tolerability of Dr Michaels® (also branded as Eczitinex® and Itchinex Eczitinex®) topical products in the treatment of atopic dermatitis in children. J BIOL REG HOMEOS AG 2016; 30:55-63. [PMID: 27498659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.
Collapse
Affiliation(s)
- K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7 Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
22
|
Gianfaldoni S, Hercogovấ J, Fioranelli M, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. An innovative, promising topical treatment for psoriasis: a Romanian clinical study. J BIOL REG HOMEOS AG 2016; 30:109-113. [PMID: 27498667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic inflammatory disease with negative impacts both physically and psychologically. It is a common disorder affecting 2-3% of the total world population, in some cases causing changes to the nail and joints as well as skin lesions. The cutaneous manifestations of psoriasis can vary in morphology and severity and therapy should be tailored accordingly. Even if today many therapeutic options are available for psoriasis treatment, none of them provide excellent clinical results without the risk of side effects. The authors investigate the efficacy of Dr. Michaels® (Soratinex®) natural products in the topical treatments of a group of psoriatic patients. Sixty-two patients (34 male/28 female) from Romania, aged 18-70 years (mean age: 52 years), affected by a mild to severe form of chronic plaque psoriasis were included in this study. Each patient has been treated with a triphasic application of Dr. Michaels® (Soratinex®) natural products, twice a day for six weeks. The products were applied on skin and scalp lesions, but not on the face, genital and flexures. The evaluation of the tested products was based on the PASI of each patient at time 0, 1, 2, 3, 4, 5, and 6 weeks. The tested products were ineffective in five of 57 patients. Eleven patients had a moderate improvement (PASI decrease 26-50%); 11 patients had a good improvement (PASI decrease 51-75%) and 30 patients an outstanding one (PASI decrease 76-100%). Twenty-three% of patients developed folliculitis that regressed upon discontinuation of the application. Five patients developed pruritus, which regressed spontaneously. The cosmetic effect was evaluated as indifferent by 44% of patients, as good by 40% of patients and as excellent by 16% of patients. Ninety-five% of patients stated that they would continue to use the tested products, because it was effective and with poor side effects since the products were natural. In our experimental study, the topical application of Dr. Michaels® (Soratinex®) natural products proved to be an effective natural therapeutic option for psoriasis treatment.
Collapse
Affiliation(s)
- S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1,Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
23
|
Tirant M, Bayer P, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Treatment of ichthyosis lamellaris using a series of herbal skin care products family. J BIOL REG HOMEOS AG 2016; 30:65-72. [PMID: 27498660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Lamellar ichthyosis (LI) is a genetically heterogeneous group of disorders of keratinization that are inherited in an autosomal recessive fashion, occurring in approximately 1 in 300,000 live births. The treatment of the large, dark, plate-like scales that characterize the classic manifestation of the disease are still a challenge. The aim of this study was to evaluate the efficacy and tolerability of Dr. Michaels® skin-care products for the management of LI. A multi-centre European prospective study was conducted, including 10 patients (3 female/7 male) with lamellar ichthyosis, aged 38-54 years old (mean age: 46). Each patient had been treated with emollients plus other different systemic therapies, such as corticosteroids, Cyclosporin A or retinoids in the past. All patients were treated with Dr Michaels® product family including both topical and oral herbal supplements. The topical treatments used were the cleansing gel, activator formula and ointment. The oral medications were PSC 200, PSC 400 and PSC 900. Within 3 weeks of initiation of treatment, there were improvements observed on the skin including a reduction in scaling, fissuring, and intensity in erythema and pruritus with thinning of the hyperkeratotic plate. After 12-15 weeks, most of the plates and scales had been removed to reveal a normalised skin colour. Evidence of hair, eyelash and eyebrow growth was observed. There was partial nail resolution with a reduction in subungual hyperkeratosis. No adverse reactions were observed. Our patients showed excellent symptomatic response to treatment within a 14-week period, follow-up by an on-going regular assessment on a quarterly basis. The results show that Dr Michaels® product family is an effective and safe treatment option for LI.
Collapse
Affiliation(s)
- M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency; Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
24
|
Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Investigation of the efficacy of Dr Michaels® (Soratinex®) family in maintaining a symptom-free state for patients with psoriasis in remission. A retrospective, comparative study. J BIOL REG HOMEOS AG 2016; 30:73-75. [PMID: 27498661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic inflammatory disease, affecting about 3% of the worldwide population. Although there are many therapeutic options available today for psoriasis, none of them can be considered as the gold standard treatment for maintaining a sustained period of remission. The aim of this study was to investigate whether a maintenance dosage of Michaels® Soratinex® product family is effective in maintaining a symptom-free state for patients in remission. Fifty patients (23 male, 27 female), aged 18-58-years-old (mean age: 38.3), affected by mild to severe plaque psoriasis (mean duration: 29.5), were included in this retrospective study. All of them had completed previous treatment and achieved remission. Twenty-eight had been previously treated with an Australian series of herbal skin-care products (Dr. Michaels® Soratinex® skincare products for psoriasis) and 22 treated with biologics. We evaluated the clinical condition of the member of each group every 4 weeks, for 16 times following remission. Maintenance group continued treatment with Dr Michaels® (Soratinex®). Non-Maintenance group discontinued both forms of treatment. The evaluation was based on the PASI score, assuming that at baseline it was zero. Out of 34 patients who continued treatment with Dr Michaels® (Soratinex®) product family in the Maintenance group (22 previously treated with Dr Michaels and 12 previously treated with Biologic), 26 remained symptom free with baseline PASI of zero. Six patients had a mild flare with a PASI increase of 0-25%. Two patients were in the moderate group with a PASI increase of 26-50% and were initially treated with biologic. Out of 6 patients in Dr Michaels non-maintenance group, 3 patients remained symptom free, 1 had a rebound starting on week 36 and 2 rebounded at week 44. Out of 10 patients who were in the non-maintenance from the biologic group, 6 rebounded at week 12, 2 rebounded at week 16, 1 rebounded at week 24 and 1 rebounded at week 32. In the maintenance group no side effects were described, except for a mild form of folliculitis in 3 patients. Treatment did not have to be discontinued and all 3 patients cleared. Based on the results of this study, Dr. Michaels® (Soratinex®) product family can be safely and successfully applied to maintain a symptom-free state, after patients go into remission following treatment with Dr. Michaels® (Soratinex®) product family or biologics in mild to very severe psoriasis, when considering the exclusion criteria.
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italyi
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
25
|
Wollina U, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Scalp psoriasis: a promising natural treatment. J BIOL REG HOMEOS AG 2016; 30:103-108. [PMID: 27498666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a lifelong chronic inflammatory disease affecting 2-3% of the worldwide population. Scalp psoriasis is a particular form of psoriasis characterized by lesions on the scalp, which may occur isolated or in association with other skin lesions. The aim of this study was to investigate the efficacy and safeness of an innovative treatment of scalp psoriasis, which is based on the topical application of natural products. Fifty adult subjects with scalp psoriasis (23 females, 27 males) from different European dermatological centres were included in the study. Forty-six patients with severely infiltrated psoriatic lesions were invited to use the products of Dr Michaels® (Soratinex®), according to a three-phase application, twice a day (morning and evening). The other 4 patients followed a different regimen: after a shampoo in the evening, they applied the conditioner in the night and washed it in the morning with the cleansing gel. The application time of Dr Michaels® (Soratinex®) products was 8 weeks. The treatment was evaluated at 0, 1, 2, 3, 4, 5, 6, 7, and 8 weeks. The evaluation was based on the Psoriasis Scalp Severity Index (PSSI) and on a photographic analysis at each of the medical evaluation points. At the end of the study, all patients showed an outstanding improvement. Five patients referred a transient pruritus, which regressed spontaneously without discontinuing the application. No other side effects have been described. We observe that Dr Michaels® (Soratinex®) natural product family can be considered as a valid therapeutic tool for scalp psoriasis when considering the exclusion criteria. The tested products provided an outstanding improvement of lesions in all the patients, without side effects.
Collapse
Affiliation(s)
- U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
26
|
Chokoeva AA, Fioranelli M, Roccia MG, Lotti T, Wollina U, Tchernev G. Giant congenital melanocytic nevus in a bulgarian newborn. J BIOL REG HOMEOS AG 2016; 30:57-60. [PMID: 27373137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Giant congenital melanocytic nevus (GCMN) is a rare disorder affecting 1 in 200,000500,000 live births. Central nervous system defects such as spina bifida, meningocele, Dandy Walker malformation may accompany it and thus cause significant morbidity. Despite the related risk for malignant transformation, GCMNs may be associated with neurocutaneous melanosis, a rare syndrome in which a giant CMN or multiple smaller CMNs are accompanied by melanocytic deposition in the brain and the spinal cord. We present a case of a 5-day-old newborn with giant congenital melanocytic nevus on his back, as we discuss the diagnostic and treatment approach.
Collapse
Affiliation(s)
- A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| |
Collapse
|
27
|
Tana C, Tchernev G, Chokoeva AA, Wollina U, Lotti T, Fioranelli M, Roccia MG, Maximov GK, Silingardi M. Pulmonary and abdominal sarcoidosis, the great imitators on imaging? J BIOL REG HOMEOS AG 2016; 30:45-48. [PMID: 27373134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Sarcoidosis is an insidious disorder that virtually affects every body organ. Lungs are the site most often affected (in up to 90% of patients) followed by intra thoracic more often than peripheral lymph nodes and other sites can be involved in different percentages. The evaluation of pulmonary sarcoidosis is best performed with high-resolution computed tomography (HRCT), as traditional chest X-ray has a low resolution and can be negative or give non-significant results. Disorders such as interstitial lung diseases (ILDs), tuberculosis, lung cancer and lymphangitis carcinomatosis can manifest with similar radiological findings that can deceive clinics and radiologists. The need of a clear distinction between these conditions is important not only for diagnostic purposes but also because treatment differs significantly in different conditions. However, conventional Ultrasound (US) can be negative if small lesions are present and false negative images can result if US is not followed by a contrast-imaging technique. Contrast enhanced computed tomography (CECT) and magnetic resonance imaging (CEMRI) are preferred to detect single or multiple masses, which appear hypodense and hypointense after contrast agent administration, respectively. We think that a correct algorithm should include a thorough clinical and radiological evaluation, a definite biopsy of affected tissues revealing classical non-caseating granulomas and a certain exclusion of conditions that can give similar clinical/histophatological patterns before considering the diagnosis of sarcoidosis. Only in these cases, a diagnosis of sarcoidosis can be sufficiently achieved before starting an appropriate treatment.
Collapse
Affiliation(s)
- C Tana
- Internal Medicine Unit, Guastalla Hospital, AUSL Reggio Emilia, Italy
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma-Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-Interventional Studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - M Silingardi
- Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA
| |
Collapse
|
28
|
Fama' F, Ieni A, Tchernev G, Chokoeva AA, Maximov GK, Wollina U, Lotti T, Patterson JW, Fioranelli M, Roccia MG, Guarneri C, Gioffre-Florio M. Pilomatrixoma of the breast in a patient with type 1 myotonic dystrophy: successful surgical approach. J BIOL REG HOMEOS AG 2016; 30:1-6. [PMID: 27373126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Malherbes calcifying epithelioma is an uncommon cutaneous tumour that originates from the matrix cells of hair follicle. It was initially described by Malherbe as a benign calcifying epithelioma. Several ultra-structural and electron-microscopic studies later demonstrated its origin from matrix cells and the term pilomatrixoma was introduced. The treatment of this tumour remains mainly surgical. Malignant cases with post-surgical recurrences have been described in literature and recurrences have been related to an incomplete surgical treatment or tumour aggressiveness. We present the case of 31-year-old female patient with pilomatrixoma of the breast, which was very similar to fibroadenoma, in terms of size and other clinical features. We successfully treated this patient surgically, and the aesthetic results were good, despite the proximity of the tumour to the areola-nipple complex. Fifteen months later, the patient is doing well, free of any clinical local recurrence.
Collapse
Affiliation(s)
- F Fama'
- Department of Human Pathology; University Hospital of Messina, Messina, Italy
| | - A Ieni
- Department of Human Pathology; University Hospital of Messina, Messina, Italy
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- "Onkoderma"- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - G K Maximov
- Department Medicinal Information and Non-Interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - J W Patterson
- University of Virginia Health System, Department of Pathology, Charlottesville, VA USA
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - C Guarneri
- Department of Clinical and Experimental Medicine, Unit of Dermatology University Hospital of Messina, Messina, Italy
| | - M Gioffre-Florio
- Department of Human Pathology; University Hospital of Messina, Messina, Italy
| |
Collapse
|
29
|
França K, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, Lotti T. A European prospective, randomized placebo-controlled doubleblind Study on the efficacy and safety of Dr Michaels® (also branded as Soratinex®) product family for stable chronic plaque psoriasis. J BIOL REG HOMEOS AG 2016; 30:9-14. [PMID: 27498652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic, inflammatory, recurrent, genetically determined dermatitis that affects the skin and joints. Many patients affected by this condition seek alternatives and complementary treatment options such as herbal medicines. In order to establish the safety of these products, trials, according to medical standards should be performed to provide the highest quality of data. The aim of this study was to assess the efficacy and safety of an Australian series of herbal skincare products [Dr. Michaels® (Soratinex®) skin-care products for psoriasis] for the management of stable chronic plaque psoriasis. We studied 142 patients (68 females and 74 males) with mild to moderate, stable, chronic plaque psoriasis and they were randomly assigned to either verum or control group. Exclusion criteria were: severe psoriasis, arthropathic psoriasis, intertriginous psoriasis, palmoplantar psoriasis, use of any antipsoriatic treatment and any medication which could influence or interfere with the course of the disease. Both groups consisted of a cleansing gel, an ointment and an oil blend (skin conditioner), packed in neutral bottles, used twice daily for all lesions except the scalp, for 8 weeks. As control products, we used compositions of well-known neutral ointments and medicinal bathing oil. Assessment, using the Psoriasis Activity Severity Index (PASI) scores, was done before treatment and after 2, 4, 6 and 8 weeks. Patient improvement was determined by the percentage reduction of the PASI scores. Statistical analysis was carried out using the Mann-Whitney-U Test with SPSS for Windows. Our investigation demonstrates that complementary methods can play a role in dermatologic therapy as long as they undergo standardised clinical trials and fulfil the basic requirements such as product safety and quality assurance. This study shows that Dr Michaels (Soratinex®) herbal skin-care products improve mild to moderate stable chronic plaque psoriasis significantly.
Collapse
Affiliation(s)
- K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine - Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa. Università Degli Studi "G. Marconi", Rome, Italy
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department, University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1,Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency Sofia, Bulgaria
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
30
|
Tirant M, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Nail psoriasis in an adult successfully treated with a series of herbal skin care products family a case report. J BIOL REG HOMEOS AG 2016; 30:21-28. [PMID: 27498654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a common chronic inflammatory dermatosis that causes significant distress and morbidity. Approximately 50% of patients with cutaneous psoriasis and 90% of patients with psoriatic arthritis demonstrate nail involvement of their psoriasis. Left untreated, nail psoriasis may progress to debilitating nail disease that leads to not only impairment of function but also on quality of life. We report the case of a 50-year-old male patient with recalcitrant nail dystrophies on the fingers since the age of 40, who responded successfully to Dr. Michaels® product family. The patient had a 35-year history of plaque psoriasis localised on the scalp, ears, groin, limbs, and trunk and with psoriatic arthritis. The nail symptoms consisted of onycholysis, onychomycosis, leukonychia, transverse grooves, nail plate crumbling and paronychia of the periungal skin. This case represents the efficacy and safety of the Dr. Michaels® (Soratinex® and Nailinex®) product family with successful resolution of nail dystrophies and surrounding paronychia with no reported adverse events.
Collapse
Affiliation(s)
- M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine - Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa. Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
31
|
Ramos O, Tchernev G, Chokoeva AA, Wollina U, Maximov GK, Patterson JW, Fioranelli M, Roccia MG, Ananiev J, Lotti T. Biofibre hair implant impact on the quality of life. J BIOL REG HOMEOS AG 2016; 30:21-25. [PMID: 27373130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Body image refers to how we feel about our bodies. It does not refer to what we actually look like, but rather to our perceptions, opinions and ways of thinking about our appearance. How we feel about our appearance is part of our body image and self-image. The hair is a significant part of this image. The problem of alopecia affects both sexes and all ages with significant sequelae. Along with androgenetic alopecia, there are forms of alopecia of various origins: traumatic, surgical, pharmacological and others. Polyamide artificial hair implant (Biofibre®) is one of the current techniques used to treat this problem.
Collapse
Affiliation(s)
- O Ramos
- Clinica Dermatologica Tavizon y Torres, Coyoacan, Distrito Federal, Mexico
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma-Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - J W Patterson
- University of Virginia Health System, Department of Pathology, Charlottesville, VA USA
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - J Ananiev
- Department of General and Clinical Pathology, Forensic Medicine and Deontology, Trakia University, Armeiska str.11, Stara Zagora, Bulgaria
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
32
|
Tirant M, Anderson P, Bayer P, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of a chronic eczema in a 48-year-old female with Dr Michaels® (Eczitinex® and Itchinex®) product family. A case report. J BIOL REG HOMEOS AG 2016; 30:35-42. [PMID: 27498656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We report the case of a 48-year-old female with chronic atopic eczema who responded successfully to Dr Michaels® (Eczitinex® and Itchinex®) product family. The patient had a 41-year history of atopic eczema and presented with erythematous, excoriated lesions with telangiectasia and scattered purpura (bruising) covering 90% of her body surface area. The patient also regularly suffered blepharitis with red, itchy, watery eyes. The patient was treated with Dr Michaels® (Eczitinex® and Itchinex®) ointment and herbal supplements and presented total resolution of the atopic eczema and underlying inflammation within 6 weeks. This case also suggests that Dr Michaels® (Eczitinex® and Itchinex®) product family is safe and effective, even in cortisone acquired sensitive skin.
Collapse
Affiliation(s)
- M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
33
|
Wollina U, Tirant M, Bayer P, Coburn M, Anderson P, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Walmsley S, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of mild to moderate acne vulgaris with Dr Michaels® (also branded as Zitinex®) topical products family: a clinical trial. J BIOL REG HOMEOS AG 2016; 30:49-54. [PMID: 27498658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Acne vulgaris is an epidemic inflammatory skin disease of multi-factorial origin, frequently seen in adolescents and often persisting or occurring through to adulthood. Acne vulgaris is a nearly universal skin disease afflicting 79-95% of the adolescent population in westernized societies and is a significant cause of psychological morbidity in affected patients. Despite the various treatment options available for acne, there is still a need for a safe and effective option. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Zitinex®) product family in the treatment of papulo-pustular acne. 25 patients (17 female/8 male), aged 15-22, with a mild to moderate papulo-pustular acne, localized on the face and on the trunk, were included in this study. None of the patients had used any other kind of treatment in the 3 months prior to commencing this study. All of the patients were treated with Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, a cream, PSC 200 and PSC 900 oral supplements. Application time of Dr Michaels® (Zitinex®) products was 12 weeks. The treatment was been evaluated clinically at 0, 4, 8 and 12 weeks. All of the patients showed an improvement in all parameters of their acne (comedones, papules, pustules, hyperpigmentation and scars). The acne lesions and erythema had mostly resolved. The hyperpigmentation and pitted scarring had significantly reduced also, with the skin appearing smoother. The treatment was well tolerated and no side effects have been described. Our study demonstrates that the Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, cream and oral supplements PSC 200 and PSC 900 are an effective therapeutic option for the treatment of moderately severe acne vulgaris. Moreover, it highlights the safety profile of the Dr Michaels® (Zitinex®) product family in a case of acne compared to traditional first-line treatments.
Collapse
Affiliation(s)
- U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - S Walmsley
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
34
|
Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Dr Michaels® product family (also branded as Soratinex®) versus Methylprednisolone aceponate - a comparative study of the effectiveness for the treatment of plaque psoriasis. J BIOL REG HOMEOS AG 2016; 30:77-81. [PMID: 27498662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
As one of the most common dermatologic chronic-recurrent disease, variable therapeutic options are available today for management of psoriasis. Although topical high potency corticosteroids, alone or in association with salicylic acid or vitamin D analogues, are still considered the best treatment, they do not seem to possess the capability for a long-term control of the disease or prevent recurrences, as their side effects are major contraindications for continuative use. The aim of this study was to investigate whether Dr. Michaels® product family is comparable to methylprednisolone aceponate (MPA) as a viable alternative treatment option for the treatment and management of stable chronic plaque psoriasis. Thirty adults (13 male, 17 female, mean age 40 years) with mild to severe stable chronic plaque psoriasis, were included in the study. Patients were advised to treat the lesions of the two sides of their body (left and right) with two different unknown modalities for 8 weeks; the pack of Dr. Michaels® products on the left side (consisting of a cleansing gel, an ointment and a skin conditioner) and a placebo pack on the right side, consisting of a cleansing gel, methylprednisolone ointment and a placebo conditioner. Assessment was done using the Psoriasis Activity Severity Index (PASI) scores before treatment and after 2, 4, 6 and 8 weeks. The results achieved with the Dr. Michaels® (Soratinex®) product family for the treatment of chronic plaque psoriasis were better than the results achieved with methylprednisolone aceponate (MPA), even though quicker resolution was achieved with the steroid with 45% of patients achieving resolution within 8-10 days in comparison to 5-6 weeks in the Dr. Michaels® (Soratinex®) group. Before therapy, the mean PASI score of the LHS in Dr. Michaels® (Soratinex®) group was 13.8±4.1 SD and 14.2±4.2 SD in the RHS methylprednisolone aceponate (MPA) group. After 8 weeks of treatment 62% of the Dr. Michaels® (Soratinex®) group had achieved resolution whilst in the methylprednisolone aceponate (MPA) group, the figure remained at 45%. The mean PASI score after 8 weeks of treatment was calculated and in the LHS Dr. Michaels® (Soratinex®) group it was 2.8±1.6 SD and 6.8±2.4 SD in the RHS methylprednisolone aceponate group. In the RHS -methylprednisolone aceponate (MPA) group, 22% of patients failed to respond to the treatment in comparison to 6% in the LHS Dr. Michaels® (Soratinex®) group. Based on the results of this study, Dr. Michaels® products are a more effective treatment option, with insignificant side effects, compared to local treatment with methylprednisolone aceponate (MPA).
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
35
|
Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. A clinical examination of the efficacy of preparation of Dr Michaels® (also branded as Soratinex®) products in the treatment of psoriasis. J BIOL REG HOMEOS AG 2016; 30:15-20. [PMID: 27498653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic inflammatory disease with negative impacts both physically and psychologically. It is a common disorder affecting 2-3% of the total world population, in some cases causing changes to the nail and joints as well as skin lesions. The cutaneous manifestations of psoriasis can vary in morphology and severity and therapy should be tailored accordingly. The aim of the study was to investigate the efficacy of Dr Michaels® (Soratinex®) product line in the treatment of psoriatic patients with different age and disease severity. A total number of 270 patients with verified psoriasis, aged 9-60 years old participated in the studies, including 128 children: 23 girls and 105 boys, (all of them selected from the Department of Dermato-allergology of the Russian Pediatric Hospital Clinic, Moscow, and of the 4th Department of Dermatology of the 52nd Moscow City Hospital Clinic). The patients were separated into 3 groups according to the severity of the disease (based on the PASI-index). All the patients have been treated with Dr Michaels® (Soratinex®) products twice daily, as three different forms were available for application: a cleansing gel, an ointment and a conditioner. The severity of the disease and the efficacy of the treatment have been defined with the evaluation of the PASI index of each patient. The obtained results were recorded in a graphic form showing the changes of the PASI-index on days 3, 7, 14, and 21 counted from the start of the trial. Clinical remission was achieved in 147 patients, a significant improvement in 73, partial improvement in 32, while no effect was seen in 12 patients and deterioration in 6. This open trial demonstrated the clinical efficacy of topical application of Dr Michaels® (Soratinex®) preparation. We observed clinical remissions of psoriasis in adults and in children.
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine - Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa. Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
36
|
França K, Tirant M, Hercogovấ J, Novotny F, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Roccia MG, Lotti T. Quality of life aspects of patients with psoriasis using a series of herbal products. J BIOL REG HOMEOS AG 2016; 30:121-127. [PMID: 27498669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic inflammatory disease affecting 1-3% of the general population. Due to the chronic nature of the disease, patients suffer from substantial psychosocial impact and impaired quality of life. Dr Michaels® (also branded as Soratinex®), an Australian series of topical herbal products, has been showing promising results for the treatment of patients with chronic plaque psoriasis and consequent improvement in their quality of life. This study aims to access the changes in quality of life of patients with Psoriasis using an Australian series of herbal skin-care products Dr Michaels® (Soratinex®) for psoriasis. The aim of this study is to observe and analyze the impact of Dr Michaels® product family on the quality of life of patients with psoriasis, 566 patients completed the Dermatology Quality of Life Index (DQLI) questionnaire in their initial consultation and at 3 follow up consultations, over a 6 months period. At the end of the data collection, all patients answers were recorded and analyzed. The Psoriasis Area and Severity (PASI) Index were used to measure the severity and extent of psoriasis during the 3 consultations. The PASI for severe, moderate-severe, mild-moderate cases across time revealed a significant effect of the treatment within weeks, confirming the decreasing scores during the treatment. As well as PASI results, the final DLQI score showed a sensible reduction from mean =6.716 (at week 0) to 6.252 (at week 2), 4.015 (at week 6) and 2.407 (at week 10) signifying a 64.2% reduction of the initial score. This study demonstrates that Dr. Michaels® (Soratinex®) products, an Australian series of herbal-based skin products is effective for the treatment of psoriasis. This treatment also significantly improves patients quality of life.
Collapse
Affiliation(s)
- K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
37
|
Klug DJ, Darling MD, Kaley JR, Tchernev G, Chokoeva AA, Wollina U, Lotti T, Fioranelli M, Roccia MG, Maximov GK, Gagnon AL, Patterson JW. Isolated CMV infection causing perianal and sacral ulceration in a patient with aids. J BIOL REG HOMEOS AG 2016; 30:13-15. [PMID: 27373128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Cytomegalovirus (CMV) is a DNA virus estimated to infect 70-90% of the worlds population, producing minimal symptoms in immunocompetent hosts. In the immunocompromised host, CMV infection can be potentially fatal, producing systemic or localized forms. We report the case of a 52-year-old female with acquired immunodeficiency virus (AIDS) who presented multiple sacral and perineal ulcers clinically and histopathologically consistent with CMV ulcerations. We discuss the patients clinical presentation and histologic findings to remind physicians to consider CMV as a cause for cutaneous and systemic infection in the immunocompromised host.
Collapse
Affiliation(s)
- D J Klug
- University of Nebraska Medical Center College of Medicine, Omaha, Nebraska
| | - M D Darling
- Departments of Pathology, University of Virginia Health System, Charlottesville, Virginia
| | - J R Kaley
- Departments of Pathology, University of Virginia Health System, Charlottesville, Virginia
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- "Onkoderma"- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-Interventional Studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - A L Gagnon
- Department of dermatology, University of Virginia Health System, Charlottesville, Virginia
| | - J W Patterson
- Departments of Pathology, University of Virginia Health System, Charlottesville, Virginia
| |
Collapse
|
38
|
Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Dr Michaels® (Soratinex®) product for the topical treatment of psoriasis: a Hungarian/Czech and Slovak study. J BIOL REG HOMEOS AG 2016; 30:43-47. [PMID: 27498657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Psoriasis is a chronic inflammatory T cell-mediated skin disease, affecting about 2% of Hungarian population. Genetic predisposition as well as environmental triggering factors, and innate immune processes play a role in its etiology. Treatment of psoriasis during the initial stages and first years of disease tend to be conservative and frequently based on topical agents. The aim of this study was to investigate and to describe the efficacy and safety of Dr Michaels® (Soratinex®) skin-care products for the topical treatment of stable chronic plaque psoriasis in a Hungarian population. Two-hundred-and-eight-six (120 female/166 male) patients, aged 10-80 years old (mean age 43 years) with mild to moderate plaque psoriasis had participated in the study. The products, including cleansing gel containing a coal tar solution, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done 2 weeks before treatment, at time 0, and after 2, 4, 6 and 8 weeks. Patients improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks treatment course, 46 patients had a moderate improvement, with the regression of 25-50% of skin lesions; 77 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 115 patients had an outstanding improvement, with the regression of 76-98.9% of lesions. Only 13 patients did not achieve an improvement of psoriasis. Fifteen patients experienced folliculitis, which resolved after cessation of treatment. Seven patients worsened and discontinued treatment. Thirteen patients dropped out because of non-compliance. Our investigation demonstrates that Dr Michaels® (Soratinex®) products, an Australian treatment, can be used successfully in the treatment of stable chronic plaque psoriasis.
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
39
|
Gagnon AL, Daniel S, Greer K, Patterson JW, Tchernev G, Chokoeva AA, Wollina U, Lotti T, Fioranelli M, Roccia MG, Guarneri C, Aguilera N. Langerhans cell sarcoma: an unusual microscopic presentation. J BIOL REG HOMEOS AG 2016; 30:39-43. [PMID: 27373133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A 70-year-old Caucasian male presented to our clinic for a pruritic eruption progressing over several months. He complained of fatigue with a 20-pound weight loss over the past year. On presentation, the patient had browny-yellow to violaceous, purpuric, macular and papular lesions on the legs, arms, lower abdomen and back. Initial biopsy showed an angiocentric infiltrate with a suggestion of intraluminal proliferation; CD31 and Fli-1 positivity suggested either reactive angioendotheliomatosis or an unusual intravascular histiocytosis. Further excisional biopsies demonstrated perivascular collections of cells with ample cytoplasm, prominent nuclear pleomorphism and mitotic activity. The nuclei demonstrated nuclear folding, grooves and indentations. The atypical cells were S100, CD1a and CD56 positive with immunohistochemistry. A diagnosis of Langerhans cell sarcoma (LCS) was made. LCS is a rare, aggressive malignancy that can involve multiple organs including the skin, lymph nodes, lung, bone marrow, spleen, heart, and brain. The skin and lymph nodes are commonly involved, and the cutaneous presentation varies greatly. Immunohistochemistry characteristically shows CD1a and S100 positivity. CD56 expression is uncommon and often portends a poor prognosis. There is no established treatment of LCS due to its rarity. Surgery, radiation, and chemotherapy have been used with varied outcomes. Our patient was treated with prednisone with improvement of cutaneous disease. He did not develop systemic involvement, but died 1.5 years later from complications associated with heart failure. Langerhans cell sarcoma should be considered when faced with an unusual angiocentric infiltrate in which initial immunohistochemical staining results may be misleading.
Collapse
Affiliation(s)
- A L Gagnon
- Department of Dermatology, University of Virginia Health System, Charlottesville, Virginia, USA
| | - S Daniel
- Departments of Pathology and Dermatology, University of Virginia Health System, Charlottesville, Virginia, USA
| | - K Greer
- Department of Dermatology, University of Virginia Health System, Charlottesville, Virginia, USA
| | - J W Patterson
- Departments of Pathology and Dermatology, University of Virginia Health System, Charlottesville, Virginia, USA
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - C Guarneri
- Department of Clinical and Experimental Medicine, Unit of Dermatology University Hospital of Messina, Messina, Italy
| | - N Aguilera
- Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA
| |
Collapse
|
40
|
Fama F, Sindoni A, Tchernev G, Chokoeva AA, Wollina U, Lotti T, Maximov GK, Patterson JW, Fioranelli M, Roccia MG, Ieni A, Cascio A, Gioffre-Florio M, Guarneri C. Uncommon clinical presentation of Kimuras disease as bilateral retroauricular masses in a young Malian male: successful surgical approach. J BIOL REG HOMEOS AG 2016; 30:35-38. [PMID: 27373132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We present a case of a 27 year-old Malian male referred to our hospital for two large, painless retroauricolar masses that had appeared two years earlier. Bilateral cervical painless lymphadenopathy was present at physical examination, without any other systemic symptoms. His history was relevant for bilateral Kimuras disease lesions resected 5 years earlier in the same locations. Lymphocytosis and a mild hypereosinophilia were found in routine blood tests, together with increased total IgE levels. After surgery, histology showed lymphoid infiltrates with reactive prominent germinal centres containing eosinophils, suggesting relapse of Kimuras disease, in the context of nonencapsulated fibrous proliferation with discontinuous collagen fibers, consistent with keloid. Three months after removal of retroauricular masses, abnormal laboratory findings reverted to normal. To the best our knowledge, this is the first case in literature of bilateral keloid lesions developed after surgery for Kimura Disease and harbouring its histopathologic features. Clinicians should be aware of these unusual reactive phenomena and their possible simulators.
Collapse
Affiliation(s)
- F Fama
- Department of Human Pathology, University Hospital of Messina, Messina, Italy
| | - A Sindoni
- Department of Biomedical and Dental Sciences and of Morphological and Functional Images, University Hospital of Messina, Messina, Italy
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - G K Maximov
- Department Medicinal Information and Non-Interventional Studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - J W Patterson
- University of Virginia Health System, Department of Pathology, Charlottesville, VA USA
| | - M Fioranelli
- History Department, G.Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - A Ieni
- Department of Human Pathology, University Hospital of Messina, Messina, Italy
| | - A Cascio
- Department of Human Pathology, University Hospital of Messina, Messina, Italy
| | - M Gioffre-Florio
- Department of Human Pathology, University Hospital of Messina, Messina, Italy
| | - C Guarneri
- Department of Clinical and Experimental Medicine - Section of Dermatology, University Hospital of Messina, Messina, Italy
| |
Collapse
|
41
|
Chokoeva AA, Fioranelli M, Roccia MG, Lotti T, Wollina U, Tchernev G. Multifocal infantile progressive hemangiomatosis with ocular involvement: unique presentation in a Bulgarian newborn. J BIOL REG HOMEOS AG 2016; 30:61-63. [PMID: 27373138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Vascular disorders are considered a common finding among infants and in general, hemangioma is the most common. Diffuse neonatal hemangiomatosis is a rare and frequently fatal variant of them. We describe a case of a 2-months-old infant with multiple cutaneous hemangiomatosis and ocular involvement. To the best of our knowledge, this is the first reported case. We focus on the different treatment modalities and current diagnostic approaches.
Collapse
Affiliation(s)
- A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - M Fioranelli
- History Department, G. Marconi University, Rome, Italy
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| |
Collapse
|
42
|
Hercogovấ J, Tirant M, Bayer P, Coburn M, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family. J BIOL REG HOMEOS AG 2016; 30:89-93. [PMID: 27498664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
43
|
Wollina U, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Tirant M, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of alopecia areata with Dr. Michaels® (Alopinex) product family. J BIOL REG HOMEOS AG 2016; 30:83-87. [PMID: 27498663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
UNLABELLED Alopecia areata is a highly prevalent organ restricted autoimmune disorder that leads to disfiguring hair loss and is thought to involve a T cellmediated response to the hair follicle. The treatment of alopecia areata is often problematic and very frustrating, partly due to the unknown aetiology of the condition. The aim of this study was to evaluate the efficacy and tolerability of complementary medicine, Dr. Michaels® product family, in the treatment of alopecia areata. MATERIALS AND METHODS 40 patients (27 female/13 male), with a mean age of 20.3 years, all of them with 1-3 lesions of stable alopecia areata localized on the scalp were included in this trial. Four patients suffered from Hashimoto thyroiditis, and one had a familial history of LES. Exclusion criteria were the use of any treatment or medication, which may influence or interfere with the course of the disease. All patients were treated with Dr. Michaels® StimOils - applied twice daily (morning and night), Hair Lotion applied twice daily (morning and night), and oral herbal formulation - PSC 900 2ml twice daily with food for 16 weeks. For each patient, photographs of typical lesions were taken at the beginning and at 4, 8, 12 and 16 weeks follow-up. Patient improvement was determined by the percentage of hair regrowth for each lesion. RESULTS After 10 weeks of treatment using StimOils, Hair Lotion and PSC 900 from Dr. Michaels® product family, 18 patients had achieved an excellent response with regrowth in all the affected alopecia areata patches. 17 patients achieved the same results after 12 weeks of treatment; the other 5 patients had to continue the therapeutic protocol for another 2-3 weeks. CONCLUSION This study demonstrates that the Dr. Michaels® StimOils, Hair Lotion and PSC 900 are an effective therapeutic option for the treatment of alopecia areata. This has important implications for resistant cases of alopecia areata where traditional systemic and topical corticosteroid therapies have failed. In addition, this treatment approach may be an attractive option for patients who have growing concern regarding side-effects of long-term corticosteroid therapy.
Collapse
Affiliation(s)
- U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
44
|
Lotti T, Hercogova J, Wollina U, Chokoeva AA, Zarrab Z, Gianfaldoni S, Roccia MG, Fioranelli M, Tchernev G. Treating skin diseases according to the low dose medicine principles. Data and hypotheses. J BIOL REG HOMEOS AG 2015; 29:47-51. [PMID: 26016968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Cytokines, hormones and growth factors, also defined with the collective name of signaling molecules are key regulating agents of physiological (and also pathological) functions according to the principles of Psycho-Neuro-Endocrine-Immunology (P.N.E.I.). From the latest evidences in the fields of Molecular Biology, P.N.E.I. and nano-concentration, a new medical approach surfaces: the Low Dose Medicine (LDM), a new tool for the study and the design of therapeutic strategies based on immune rebalance interventions. LDM suggest the use of low-doses of activated signaling molecules in order to restore P.N.E.I. homeostatic conditions and an increasing number of scientific evidences of LDM approach efficacy and safety support LDM-based therapeutic approach for the treatment of many dermatological diseases such as Psoriasis Vulgaris, Vitiligo and Atopic Dermatitis.
Collapse
Affiliation(s)
- T Lotti
- Professor and Chair of Dermatology, University of Rome G.Marconi, Rome, Italy
| | - J Hercogova
- Dept. Dermatology, 2nd Medical School, Charles University, Prague
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - A A Chokoeva
- Onkoderma-Policlinic for Dermatology, Venereology and Dermatologic surgery, Sofia, Bulgaria
| | - Z Zarrab
- University of Rome G. Marconi, Rome, Italy
| | - S Gianfaldoni
- Department of dermatologic Sciences, University of Florence, Florence, Italy
| | | | - M Fioranelli
- Associate Professor of Physiology, University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G Tchernev
- Onkoderma-Policlinic for Dermatology, Venereology and Dermatologic surgery, Sofia, Bulgaria
| |
Collapse
|
45
|
Lotti T, Hercogova J, Wollina U, Chokoeva AA, Zarrab Z, Gianfaldoni S, Roccia MG, Fioranelli M, Tchernev G. Psycho-neuro-endocrine-immunology and low dose cytokines therapy: principles and evidences for an innovative medical approach in acute and chronic inflammatory diseases. J BIOL REG HOMEOS AG 2015; 29:37-45. [PMID: 26016967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The development of the Psycho-Neuro-Endocrine-Immunology (P.N.E.I.), induced a fundamental paradigm shift in the interpretation of the biological functions of the body; from a separatist point of view to an unifying one, centered on the recognized importance of the cross-talk between cells, organs and systems. This interplay is regulated by a great number of messenger molecules and their circulating levels are key parameters for the definition of both physiological and pathological conditions; indeed, the pathological phenomenon can be described as an imbalance in intercellular signaling. The restoration of the impaired signalling molecules balance is the goal of Low Dose Medicine (LDM), a new medical approach based on the administration of low physiological doses of messenger molecules (which act as homeostatic modulating agents). The validity of the Low Dose Medicine conceptual approach in terms of efficacy and safety is assessed by five years of scientific research in this field. In particular the role of low dose Sequential Kinetic Activation (SKA) signalling molecules oral administration in inflammatory status management is demonstrated.
Collapse
Affiliation(s)
- T Lotti
- Professor and Chair of Dermatology, University of Rome G.Marconi Rome, Italy
| | - J Hercogova
- Dept. Dermatology, 2nd Medical School, Charles University, Prague
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - A A Chokoeva
- Onkoderma -Policlinic for Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - Z Zarrab
- University of Rome G. Marconi, Rome, Italy
| | - S Gianfaldoni
- Department of dermatologic Sciences, University of Florence, Florence, Italy
| | | | - M Fioranelli
- Associate Professor of Physiology, University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G Tchernev
- Onkoderma -Policlinic for Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| |
Collapse
|
46
|
Lotti T, Hercogova J, Wollina U, Chokoeva AA, Zarrab Z, Gianfaldoni S, Roccia MG, Fioranelli M, Tchernev G. Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments. J BIOL REG HOMEOS AG 2015; 29:53-58. [PMID: 26016984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The current treatments for Vitiligo are not completely satisfactory in terms of clinical, aesthetic and compliance results for patients. Recently, combination therapies had been introduced with positive results. In this paper the combination between systemic oral treatment with Low Dose Cytokines in association with other topical treatments was evaluated. Positive results were obtained both with Low Dose Cytokines alone or in association with microphototherapy with positive percentage of skin repigmentation varying between 74% and 90%. Collected data allow the authors to affirm that the treatment with oral low dose SKA drugs is efficacious per se and highly efficacious in association with targeted phototherapy.
Collapse
Affiliation(s)
- T Lotti
- Professor and Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| | - J Hercogova
- Dept. Dermatology, 2nd Medical School, Charles University, Prague, Czech Republic
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - A A Chokoeva
- Onkoderma-Policlinic for Dermatology, Venereology and Dermatologic surgery, Sofia, Bulgaria
| | - Z Zarrab
- University of Rome G. Marconi, Rome, Italy
| | - S Gianfaldoni
- Department of dermatologic Sciences, University of Florence, Florence, Italy
| | | | - M Fioranelli
- Associate Professor of Physiology, University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G Tchernev
- Onkoderma-Policlinic for Dermatology, Venereology and Dermatologic surgery, Sofia, Bulgaria
| |
Collapse
|